Key Takeaways Focus on specialty drugs, biosimilars, and novel therapies, combined with global partnerships, drives growth, revenue stability, and improved operating margins. Strategic investments in manufacturing, regulatory compliance, and CDMO expansion enable market diversification, higher margins, and stronger global competitiveness.Read more
Key Takeaways Global commercial expansion in complex portfolios, strong partnerships, and rapid biologics rollout could lead to revenue and margin growth beyond current expectations. Investments in automation, integration, and regulatory compliance position Shilpa for sustained cost advantages, operational excellence, and robust long-term profitability.Read more
Key Takeaways Shilpa Medicare faces structural threats from shifting industry trends, heightened global regulation, and intense competition, all challenging its core business model and revenue growth prospects. Ongoing heavy investments in innovation and capacity expansion carry high execution risk, with potential cash flow strain and increased debt if approvals or market uptake underperform.Read more
Shilpa Medicare Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, biosimilars, and contract development and manufacturing organisation in India, the United States, Europe, and internationally. The company offers various oncology and non-oncology APIs, such as anastrozole, acebrophylline, ambroxol hydrochloride, axitinib, azacitidine, abiraterone acetate, bendamustine HCL monohydrate, bicalutamide, bortezomib, busulphan, cabazitaxel amorphous, capecitabine, clofarabine, cyclophosphamide, dasatinib, decitabine, dimethyl fumarate, erlotinib HCL, enzalutamide, fingolimod hydrochloride, gemcitabine HCl, ibrutinib, imatinib mesylate, irinotecan HCl trihydrate, lenalidomide, lenvatinib mesylate, letrozole, and melphalan HCL. It also provides nifedipine, oxaliplatin, pazopanib, pemetrexed disodium hemipentahydrate, pemetrexed dipotassium nonahydrate, pirfenidone, pomalidomide, sodium cholesteryl sulfate, sorafenib tosylate, sunitinib malate, temozolomide, teriflunomide, thalidomide, tranexamic and zoledronic acid, phenylephrine, citicholine, palbocicilib, nilotinib, nintedanib, praziquintol, carmustine, elthrombopag olamine, abacavir sulphate, tenofovir disproxyl fumarate API, tenofovir alfanamide, prucalopride succinate, and varenicline tartrate. In addition, the company offers intermediates; peptides; biopolymers; biologics; contract development and manufacturing services; and formulations, such as tablets, capsules, liquid injections, dry powder injectable products, oral dissolving films, transdermal patches. Further, it is involved in the manufacture of specialized oncology formulations; and wind power generation activities. The company was formerly known as Shilpa Antibiotics Ltd and changed its name to Shilpa Medicare Limited in February 2003. Shilpa Medicare Limited was incorporated in 1987 and is based in Raichur, India.
